Aims: Cyclosporin A (CyA) has potent inhibitory activity on organic anion transporting polypeptide 1B (OATP1B), causing drug-drug interactions with its substrate drugs. 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), a uraemic toxin, has also been suggested to inhibit OATP1B activity. Recent study has identified coproporphyrin-I (CP-I) as a specific endogenous substrate for OATP1B, which is useful to indicate OATP1B activity. We investigated the relationship of CP-I with CyA and CMPF concentrations in patients taking CyA.
Methods: In total, 121 blood samples from 74 patients who took CyA and underwent routine therapeutic drug monitoring were divided into trough and peak samples.
Results: CyA and CP-I concentrations were significantly higher in peak samples than in trough samples. A positive correlation between CP-I and CyA concentrations was found in all samples and in trough and peak samples, while no correlation was observed between CP-I and CMPF concentrations. Multiple regression analysis identified CyA and C-reactive protein concentrations as independent factors affecting CP-I concentration, with blood CyA concentration having markedly greater contribution to plasma CP-I concentration.
Conclusion: The present study suggests that CyA inhibits OATP1B activity in a concentration-dependent manner in clinical setting, and that dose adjustment of OATP1B substrate drugs coadministered with CyA according to plasma CMPF concentration may not be necessary.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcp.15640 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-Sensitive Quantification of Coproporphyrin-I and -III in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry.
ACS Omega
November 2024
Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan.
Organic anion transporting polypeptides (OATP) 1B1 and 1B3 are expressed in liver cells and are involved in drug uptake in the liver. OATP1B activity varies due to polymorphisms and is decreased by OATP1B inhibitors. Variability of OATP1B activity impacts the pharmacokinetics of OATP1B substrate drugs through drug-drug interactions.
View Article and Find Full Text PDFIncreased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe.
Clin Transl Sci
October 2024
Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Ezetimibe undergoes glucuronidation that results in the active metabolite ezetimibe phenoxy-glucuronide (ezetimibe-glucuronide). This phase-II metabolite was shown to interact with the clinically relevant hepatic transporter organic anion transporting polypeptide (OATP) 1B1. In recent years, coproporphyrin I (CPI) was established as a Tier 1 biomarker for OATP1B-mediated interactions among other endogenous substrates like CPIII.
View Article and Find Full Text PDFInnovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies.
Pharmaceutics
July 2024
Scientific Affairs, Celerion, Belfast BT9 6AD, UK.
Of the 450 cell membrane transporters responsible for shuttling substrates, nutrients, hormones, neurotransmitters, antioxidants, and signaling molecules, approximately nine are associated with clinically relevant drug-drug interactions (DDIs) due to their role in drug and metabolite transport. Therefore, a clinical study evaluating potential transporter DDIs is recommended if an investigational product is intestinally absorbed, undergoes renal or hepatic elimination, or is suspected to either be a transporter substrate or perpetrator. However, many of the transporter substrates and inhibitors administered during a DDI study also affect cytochrome P450 (CYP) activity, which can complicate data interpretation.
View Article and Find Full Text PDFCharacterization and Prediction of Organic Anion Transporting Polypeptide 1B Activity in Prostate Cancer Patients on Abiraterone Acetate Using Endogenous Biomarker Coproporphyrin I.
Drug Metab Dispos
October 2024
Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)
Article Synopsis
- This study investigates how the cancer treatment drug abiraterone affects the liver transport proteins OATP1B1 and OATP1B3, focusing on the use of coproporphyrin I (CP-I) as a biomarker to measure these effects.
- The results showed that abiraterone inhibits the uptake of CP-I through OATP1B3 but not OATP1B1, with in vitro tests revealing a moderate inhibition constant and clinical simulations indicating no significant drug interaction.
- Overall, the findings suggest that the risk of interaction between abiraterone and other drugs that rely on OATP1B transporters is low, meaning that OATP1B3 does
Relationship of plasma 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease.
Clin Transl Sci
February 2024
Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
Organic anion-transporting polypeptides (OATP)1B are drug transporters mainly expressed in the sinusoidal membrane. Many studies have suggested that OATP1B activity is affected by genetic factor, the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), and inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Coproporphyrin-I (CP-I) is spotlighted as a highly accurate endogenous substrate of OATP1B.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!